Pathology and treatment of mouse models of dominant retinal disease
Pathology and treatment of mouse models of dominant retinal disease
批准号:
G0801004/1
负责人:
Robin Ali
金额:
$54.31万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2008
资助国家:
英国
项目状态:
已结题
起止时间:
2008 至 --
中文摘要
遗传性视网膜疾病影响我们最宝贵的感觉,视力,约1/3000的人口。这些疾病中的许多导致视力完全丧失失明,不幸的是,目前还没有有效的治疗方法。开发治疗方法的一个主要困难是无法从患者身上采集视网膜组织样本,以充分了解疾病的发展过程或测试可能进一步损害有限视力的新治疗方法。动物模型的使用避免了这些问题,但要有意义,它们需要准确地模拟人类疾病。这意味着必须研究相同的基因突变。这种突变通常在自然界中找不到,因此必须在动物中靶向与人类相同的基因,以便引入相同的突变。这些都是复杂、耗时和昂贵的实验,因此充分利用这些人类疾病模型非常重要。我们已经建立了两个这样的模型,其中人类基因突变负责基本的视觉过程,导致视网膜中感光细胞的损失。我们建议使用这些模型来详细了解视网膜变性的过程,并随后评估潜在的治疗方案,其中包括测试各种药物,生长因子和使用病毒载体递送到眼睛的基因替代疗法。这将使我们能够确定患者的治疗方法,并为临床试验迈出第一步。
英文摘要
Hereditary retinal disease affects our most precious sense, sight, in about 1 in 3000 of the population. Many of these disorders cause complete loss of vision blindness and, unfortunately, there is as yet no effective treatment. A major difficulty in developing treatments is the inability to sample retinal tissues from patients in order to fully understand how the disease develops or to test novel treatments that may further compromise limited vision. The use of animal models avoids these problems but, to be meaningful, they need to accurately mimic the human disorder. This means that the same gene mutation must be studied. Such mutations are generally not found in nature so the same gene as in human must be targeted in the animal so that the same mutation is introduced. These are complex, time-consuming and expensive experiments, so it is important that such models of human disease are fully exploited. We have already generated two such models with human mutations in genes responsible for basic visual processes resulting in the loss of light sensitive cells in the retina. We propose to use these models to gain a detailed understanding of the process of retinal degeneration and to follow this with an assessment of potential treatment options that will include the testing of various drugs, growth factors and gene replacement therapy using viral vectors delivered to the eye. This will enable us to determine the treatment for patients and will provide the first step towards a clinical trial.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
King's/Royal Free/UCL Gene Therapy Innovation Hub
-
批准号:MR/V030191/1
-
项目类别:Research Grant
-
资助金额:$773.14万
-
财政年份:2021
-
负责人:Robin Ali
-
依托单位:
Clinical trial of cone photoreceptor transplantation for the treatment of retinal degeneration
-
批准号:MR/V038559/1
-
项目类别:Research Grant
-
资助金额:$543.51万
-
财政年份:2021
-
负责人:Robin Ali
-
依托单位:
Improving functional connectivity following transplantation of cone photoreceptors
-
批准号:MR/T002735/2
-
项目类别:Research Grant
-
资助金额:$244.0万
-
财政年份:2020
-
负责人:Robin Ali
-
依托单位:
Improving functional connectivity following transplantation of cone photoreceptors
-
批准号:MR/T002735/1
-
项目类别:Research Grant
-
资助金额:$299.0万
-
财政年份:2019
-
负责人:Robin Ali
-
依托单位:
Clinical trial of gene therapy for the treatment of Leber congenital amaurosis
-
批准号:MR/M015815/1
-
项目类别:Research Grant
-
资助金额:$380.54万
-
财政年份:2015
-
负责人:Robin Ali
-
依托单位:
Optimisation of human ESC-derived photoreceptor cell differentiation
-
批准号:MR/M007871/1
-
项目类别:Research Grant
-
资助金额:$142.3万
-
财政年份:2014
-
负责人:Robin Ali
-
依托单位:
Clinical trial of gene therapy for the treatment of achromatopsia
-
批准号:MR/K025589/1
-
项目类别:Research Grant
-
资助金额:$274.29万
-
财政年份:2013
-
负责人:Robin Ali
-
依托单位:
A flow cytometry facility for ocular regenerative medicine
-
批准号:MR/L012758/1
-
项目类别:Research Grant
-
资助金额:$85.96万
-
财政年份:2013
-
负责人:Robin Ali
-
依托单位:
Development of stem cell therapy to restore photopic vision
-
批准号:MR/J004553/1
-
项目类别:Research Grant
-
资助金额:$293.85万
-
财政年份:2012
-
负责人:Robin Ali
-
依托单位:
Development of an AAV vector for treatment of inherited retinal dystrophy caused by RPE65 deficiency
-
批准号:MR/J005215/1
-
项目类别:Research Grant
-
资助金额:$38.79万
-
财政年份:2011
-
负责人:Robin Ali
-
依托单位:
Development of stem cell therapy for the treatment of retinal degneration
-
批准号:G0700438/1
-
项目类别:Research Grant
-
资助金额:$195.02万
-
财政年份:2008
-
负责人:Robin Ali
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
-
批准号:82371144
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:汪雪玲
-
依托单位:
噬菌体靶向肠道粪肠球菌提高帕金森病左旋多巴疗效的机制研究
-
批准号:82371251
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:肖勤
-
依托单位:
基于密度泛函理论金原子簇放射性药物设计、制备及其在肺癌诊疗中的应用研究
-
批准号:82371997
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张春富
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
基于仿生矿化法构建氢离子捕获的炎症调节性水凝胶微球在卒中治疗中的研究
-
批准号:82372120
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:阮慧瞳
-
依托单位:
MICA基因及其抗体在肾移植排斥反应中的作用机制与干预策略研究
-
批准号:30872530
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2008
-
负责人:侯建全
-
依托单位: